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Introduction: Graft-versus-host disease (GVHD) is a common and serious complication after allogeneic stem cell transplantation (allo-
SCT). However, a similar syndrome has been reported after autologous stem cell transplantation (ASCT) as well. Case report: A 61-year-
old female diagnosed with immunoglobulin (Ig) G lambda multiple myeloma completed 10 cycles of bortezomib, thalidomide, and 
dexamethasone (VTD) and 2 cycles of cyclophosphamide, thalidomide, and dexamethasone (CTD). High-dose of melphalan (200 mg/kg) 
was given as conditioning, followed by an infusion of 2.5 × 106 CD34+ cells/kg. Three months later, she received her second ASCT. On 
Day +25 after tandem ASCT, the patient developed a maculopapular, itchy skin rash, which covered her face, trunk, and limbs. A skin 
biopsy was in line with the diagnosis of GVHD. The other organs were not involved. Treatment with systemic and local corticosteroids 
(CSs) resulted in the improvement of skin lesions, but the CSs were slowly tapered due to toxicity. In the following weeks, she developed 
symptoms of liver and gut involvement, which were resistant to steroids. The introduction of other immunosuppressive agents failed to 
achieve a response. As a consequence, she had cytomegalovirus (CMV) reactivation, as well as pancytopenia, and eventually, she died of 
infectious complications. Conclusions: GVHD after ASCT remains a rare but life-threatening complication with poor prognosis.
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Introduction
Graft-versus-host disease (GVHD) after autologous stem cell 
transplantation (ASCT) is a rare complication, but it can have a major 
impact on disease course and survival. Autologous GVHD is thought 
to occur in approximately 5% of transplanted patients [1]. Acute GVHD 
(aGVHD) is usually reported after allogeneic stem cell transplantation 
(allo-SCT) and is caused by donor T-cell recognition of recipients’ minor 
histocompatibility antigens followed by organ-specific attack [2, 3]. 
However, in the context of ASCT, the pathomechanism of GVHD 
remains unclear. Malfunctioning of regulatory T-lymphocytes, leading 
to the creation of autoreactive T-cells as a result of hematological 
malignancy itself, remains one reliable explanation [4]. Another 
hypothesis suggests that some of the maternal cells transmitted during 
fetal development may persist in adult life, leading to microchimerism, 
which has been proved to be related to certain types of autoimmune 
diseases and might trigger GVHD [5]. Auto-GVHD can appear either 
spontaneously, without any previous immunosuppressive therapy 
[1, 6, 7], or be triggered by immunomodulatory drugs [8, 9], e.g., by 
cyclosporin A withdrawal, which is thought to be attributable to self-
reactive CD8+ T-cells escaping apoptosis. It can affect only a single 
organ (e.g., skin or gastrointestinal tract) or may present with multiorgan 
involvements [1, 7, 10–15]. The differential diagnosis of auto-GVHD 
is difficult and requires the exclusion of other probable causes of the 
reported abnormalities. Although this pathology may easily be confused 
with other conditions, it is potentially curable if promptly and correctly 
diagnosed [11].
Herein, we report a case of severe acute auto-GVHD in a patient who 
underwent tandem ASCT for multiple myeloma (MM). In this case, 
the disease affected the skin, gut, and liver and was unresponsive to 
corticosteroids (CSs) and other immunosuppressants. No similar case 
has been reported in the Polish literature so far.
Case report
A 61-year-old female diagnosed with immunoglobulin (Ig) G lambda 
MM, International Staging System (ISS) = 1, standard cytogenetic 
risk group, completed 10 cycles of treatment with bortezomib, 
thalidomide, and dexamethasone (VTD) and 2 cycles of treatment with 
cyclophosphamide, thalidomide, and dexamethasone (CTD), achieving 
partial response a year later. Cytomegalovirus (CMV) serological 
status before the transplant was as follows: CMV IgM negative and 
CMV IgG positive. A total dose of 350 mg of melphalan (MEL) was 
given as conditioning, followed by her first ASCT (transplantation dose 
of 2.5 × 106 CD34+ cells/kg and 9.24 × 108 nucleated cells (NCs)/kg), 
with no serious complications. The patient regenerated and achieved 
normal blood count. Three months later, she received tandem ASCT 
due to the presence of partial response. The conditioning consisted of 
MEL 200. The total number of transplanted CD34+ and NC cells was 
2.76 × 106/kg and 13.83 × 108/kg, respectively. On Day +5 post-ASCT, 
she developed fever. Chest X-ray findings, together with an elevated 
C-reactive protein (CRP) level, were suggestive of pneumonia. The 
introduction of empiric antibiotics and antifungal agents resulted in 
pneumonia resolution; however, the fever did not subside. Of note is 
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that blood culture tests were negative. On Day +25 after ASCT, a 
diffuse, erythematous, maculopapular, and itchy skin rash covered 
her body. The appearance of skin lesions and physical examination 
were suggestive of cutaneous aGVHD. A skin biopsy revealed basal 
vacuolar degeneration and sparse inflammatory infiltration in the 
dermis, which was in line with the diagnosis of GVHD (Fig. 1, Fig. 2). 
At that time, the other organs were not involved. Treatment with 
systemic and local CSs resulted in the improvement of skin lesions, 
but the CSs were slowly tapered due to the occurrence of side 
effects. Furthermore, at Day +53 post-ASCT, a polymerase chain 
reaction (PCR) test revealed CMV reactivation with 77,000 copies/
mL; thus, valganciclovir was used at a dose of 900 mg twice daily for 
2 weeks. Within 2 weeks, CMV was eradicated, but she remained 
pancytopenic, probably due to the drug’s myelosuppressive effect. 
At Day +100 following ASCT, the patient was urgently admitted with 
gastrointestinal symptoms presenting as persistent diarrhea (stools: 
7 to 8 times/day), poor appetite, general weakness, and weight loss. 
Her skin became dry and peeling, with patches of pigmentation on the 
chest, abdomen, back, and limbs. Colon biopsy was not performed 
due to the patient’s overall bad condition. CMV test by PCR was 
negative at that time. Immunosuppressive treatment consisting of 
methylprednisolone, mycophenolate mofetil, and tacrolimus was 
initiated; however, the disease persisted. A severe variant of steroid-
resistant GVHD was diagnosed. As a consequence, second CMV 
reactivation was demonstrated (Day +110; copy number: 37,000/
mL). Treatment with ganciclovir was initiated, but the patient 
showed deepening of her pancytopenia and became  dependent 
on transfusion. Bone marrow examination revealed mild dysplasia. 
In the following months, the patient’s general condition continued to 
deteriorate, and she finally expired due to infectious complications. 
Autopsy was not performed as the patient died in a local hospital.
Discussion
MM represents the most common indication for ASCT. Studies 
have shown that this procedure, in combination with high-dose 
chemotherapy, results in an improvement in complete remission (CR) 
rates and prolongs both progression-free survival (PFS) and overall 
survival (OS) [16, 17, 18]. Of note is that auto-GVHD occurs usually 
in patients undergoing transplantation for MM [7]. Interestingly, auto-
GVHD was demonstrated in 5 out of 223 transplanted MM patients 
in the study reported by Drobyski et al. [7] but in none of the 136 
patients who underwent ASCT for acute myeloid leukemia (AML), 
non-Hodgkin lymphoma (NHL), or Hodgkin disease. Batra et al. 
[15] described eight MM patients who developed auto-GVHD after 
ASCT. All these patients presented with skin rash; six of them had 
diarrhea, and three showed elevated levels of transaminases. It 
has been hypothesized that MM patients can become predisposed 
to the development of auto-GVHD through the dysregulation of the 
immune response resulting from the myeloma itself, prior treatment 
with immunomodulatory agents, or the conditioning regimen. It is 
postulated that newer drugs used for MM treatment, e.g., bortezomib 
or lenalidomide, can alter the regulatory T-cell function and trigger 
the overproduction of autoreactive lymphocytes, which could 
potentially lead to GVHD [5, 9]. Dhodapkar et al. [19] suggested 
that a higher percentage of Th17 cells in the bone marrow of MM 
patients, compared to the figure in patients with other monoclonal 
gammopathies, may predispose to the development of auto-GVHD 
in the former group. These Th17 cells participate in the pathogenesis 
of inflammatory autoimmune diseases and, therefore, may lead to 
auto-GVHD as a form of autoimmunity among susceptible patients 
[15, 19]. According to these data, it is of high importance to be aware 
of the risk of development of auto-GVHD, especially in MM patients.
In contrast to allogeneic GVHD, auto-GVHD usually manifests in a 
milder form, and symptoms in most patients resolve spontaneously 
or respond to CSs [9, 14]. However, there have been reports 
suggesting that auto-GVHD can run a more severe course, being 
unresponsive to CSs particularly in MM patients [1, 6, 7, 15]. Batra 
et al. [15] reported six patients who did not respond well to CS 
treatment. In all the five patients mentioned in the study by Drobyski 
Fig 1. There are infiltrates of T-lymphocytes (CD3+) in the sub-
epithelial layer of the dermis surrounding the extended small 
vessels. Focal vacuolar degeneration of the basal cell layer is 
also seen. Single eosinophilic degeneration in the subepider-
mal layer is seen (hematoxylin and eosin stain)
Fig.2. Anti-CD3 antibody immunostaining of the skin revealed 
the presence of T-cells in the subepithelial layer of the dermis
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et al. [7], response to CSs was unsatisfactory, indicating steroid-
refractory GVHD. The patients underwent tandem transplantation, 
and three out of the five eventually died. The frequency of auto-
GVHD after ASCT was estimated to be around 12% in patients who 
had undergone tandem transplantations, whereas it was only 1% in 
patients after a single procedure. It was speculated that repeated 
exposure to high-dose conditioning regimen within a short period of 
time may destabilize endogenous peripheral regulatory mechanisms, 
predisposing patients to autoimmunity [7]. One study demonstrates 
the negative impact of MEL on T-cell function and suggests that this 
effect might be amplified during the second transplant [6]. Hence, 
it seems that the number of prior autologous transplantations for 
MM may play a role in the development of this rare complication [7]. 
Moreover, the low number of CD34+ cells infused each time to the 
patient might also play an important role in the post-ASCT outcome. 
It might contribute to the pancytopenia and worsen the patient’s 
immunity. It is well known that the development or exacerbation of 
GVHD favors the reactivation of CMV, e.g., due to the release of 
inflammatory mediators and by increasing immunosuppression. 
CMV reactivation in ASCT recipients remains a rare complication; 
however, it was seen in 11% of autotransplanted patients [20]. 
Returning to our case, analysis of CMV serological status by PCR 
was performed at the early onset of skin lesions; however, the clinical 
picture was suggestive for GVHD. Of note is that the cutaneous 
manifestation of CMV is extremely rare, with about 60 cases reported 
in the English literature so far. It usually presents as ulcers located in 
the perianal and genital regions, and the histological picture includes 
nuclear inclusions [21]. Such a manifestation was not demonstrated 
in our patient. CMV reactivation was also not detected at the time 
of occurrence of gastrointestinal symptoms, and therefore, CMV 
enteritis was not taken into consideration. It should be underlined 
that only PCR and histological examination performed on a colon 
biopsy would resolve this clinical dilemma. Auto-GVHD can manifest 
similar to GVHD after allogeneic transplantation [7, 12]. Cutaneous 
involvement has been reported to be the most frequent manifestation 
in auto-GVHD, followed by gastrointestinal tract involvement. 
However, among the nine cases of auto-GVHD reported by Lazarus 
et al. [9], involvement of the gastrointestinal tract predominated, while 
only one patient presented skin manifestations. The least frequently 
targeted organ was the liver [1, 9].
Some disorders can mimic the pathological and clinical changes of 
the disease, and, therefore, be misleading, but GVHD cannot easily 
be distinguished without endoscopy and mucosal biopsy [9]. The 
differential diagnosis should take into account viral reactivation and 
side effects of administered drugs. Biopsy of affected organs remains 
a gold standard in GVHD diagnosis; however, it is not routinely 
performed.
Conclusions
GVHD is an extremely rare complication after autologous 
transplantation; the treatment does not differ from that for patients after 
allo-SCT, and the general prognosis is usually poor when the disease 
is steroid refractory. Early recognition of auto-GVHD symptoms is of 
high importance for the prompt initiation of appropriate treatment and 
the avoidance of potentially life-threatening consequences.
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